Previous Close | 12.56 |
1-Year Change | 63.54% |
6-Months Change | 160.04% |
3-Months Change | -10.67% |
Moving Avg (50d) | 13.014 |
Moving Avg (200d) | 8.737 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.49B |
Beta (3-Years) | 1.99 |
Revenue Growth (ttm) | -43.15% |
Net Profit Margin (ttm) | -52.29% |
Return On Assets (ttm) | -33.12% |
EPS (ttm) | -6.38 |
PE Ratio (ttm) | -1.97 |
Dividend Yield | % |
Asset Description: | Novavax, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
12.811 | 13.188 | 13.439 | 13.816 | 14.444 | 15.072 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |